Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: Treatment with full-dose cyclophosphamide-doxorubicin- vincristine-prednisone without routine use of granulocyte-colony stimulating factor

European Journal of Cancer Care

Volumn 15, Issue 5, 2006, Pages 493-496

  Hernandez D E ^a,c   Hernandez A E ^b  

^a Hospital Vargas de Caracas   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c NONE   (Venezuela)

Author keywords

G CSF; HIV; Non Hodgkin's lymphoma

Indexed keywords

EID: 33845463795     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2006.00704.x     Document Type: Article

References (11)

1. Carbone P.P., Kaplan H.S., Musshiff K., Smithers D.W. & Tubiana M. (1971) Report of the committee on Hodgkin's disease staging classification. Cancer Research 31, 1860-1861.
2. Gill P., Levine A.M., Krailo M., Rarick M.U., Loureiro C., Deyton L., Meyer P. &. Rasheed S. (1987) AIDS-related malignant lymphoma: results of prospective treatment trials. Journal of Clinical Oncology 5, 1322-1328.
3. Harnly M.E., Swan S.H., Holly E.A., Kelter A. & Padian N. (1988) Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS). American Journal of Epidemiology 128, 261-267.
4. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., Feld R., Pizzo P.A., Rolston K.V.I., Shenep J.L. &. Young L.S. (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectiuos Disease 34, 730-751.
5. Kaplan L.D., Abrams D.I., Feigel E., McGrath M., Kahn J., Neville P., Ziegler J. & Volberding P.A. (1989) AIDS-associated non-Hodgkin's lymphoma in San Francisco. Journal of American Medical Association 261, 719-724.
6. Kaplan L.D., Kahn J.O., Crowe S., Northfelt D., Neville P., Grossberg H., Abrams D.I., Tracey J., Mills J. & Volberding P.A. (1991) Clinical and virologic effects of recombinant human granulocyte-colony stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Journal of Clinical Oncology 9, 929-940.
7. Kaplan L.D., Strauss D.J., Testa M.A., Von Roenn J., Dezube B.J., Cooley T.P., Herndier B., Northfelt D., Huang J., Tulpule A. & Levine A.M. (1997) Low-dose compared with standard-dose m BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. New England Journal of Medicine 336, 1641-1648.
8. National Cancer Institute (1982) National Cancer Institute sponsored study classifications of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical stage. Cancer 49, 2112-2135.
9. National Cancer Institute (USA) (1988) National Cancer Institute: Common Toxicity Criteria.
10. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., Schiffer C.A., Smith T.J., Somlo G., Wade J.C., Wade III J.L., Winn R.J., Wozniak A.J. & Somerfield M.R. (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Journal of Clinical Oncology 18, 3558-3585.
11. Ratner L., Lee J., Tang S., Redden D., Hamzeh F., Herndier B., Scadden D., Kaplan L., Ambinder R., Levine A., Harrington W., Grochow L., Flexner C., Tan B. & Strauss D. (2001) Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. Journal of Clinical Oncology 19, 2171-2178.